Neuralink loses brain electrodes in 1st patient

Today’s Big News

May 10, 2024

MacroGenics' stock crashes after 5 deaths in ADC trial


Sanofi keeps Novavax afloat with $1.2B bet on its vaccine platform


First Neuralink patient sees some implanted electrodes lose connection to brain


Roche’s soaring Vabysmo sales raise the stakes in ophthalmology face-off with Regeneron’s Eylea: analyst


Chutes & Ladders—Sanofi CSO steps down


House's updated biosecurity bill sets 2032 decoupling deadline for industry's work with WuXi AppTec, WuXi Biologics


Salix adds melody to Xifaxan campaign, running TV spot with 'Scandal' actor Bellamy Young

 

Featured

MacroGenics' stock crashes after 5 deaths in ADC trial

MacroGenics’ safety woes have followed into phase 2. Having dialed down the dose in response to early-phase data, the biotech's stock cratered after reporting five deaths alongside an over 50% rate of grade 3 or worse adverse events.
 

Top Stories

Sanofi keeps Novavax afloat with $1.2B bet on its vaccine platform

After years of missteps in developing and commercializing its coronavirus shot, Novavax is turning to one of the biopharma industry’s most experienced vaccine companies to help salvage its COVID efforts. Sanofi will partner with the struggling Maryland biotech to co-commercialize its COVID-19 jab Nuvaxovid and develop combination vaccines.

First Neuralink patient sees some implanted electrodes lose connection to brain

About 100 days after implanting its first human participant with its brain-computer interface chip, Neuralink reported that some of the hair-thin connecting wires laced into the tissue have stopped reporting back data.

Roche’s soaring Vabysmo sales raise the stakes in ophthalmology face-off with Regeneron’s Eylea: analyst

Roche’s long-awaited challenge to Regeneron’s dominance in the ophthalmology market may soon be coming to a head, according to a recent analyst report from GlobalData.

Chutes & Ladders—Sanofi CSO steps down

Sanofi's CSO has left the company amid a global R&D restructuring. Pfizer tags longtime Citi analyst for C-suite-level strategy role. Acelyrin's found CEO shocking leaves.

House's updated biosecurity bill sets 2032 decoupling deadline for industry's work with WuXi AppTec, WuXi Biologics

Right after an industry survey suggested that switching away from Chinese CDMOs could take biopharma companies up to eight years, lawmakers have adjusted the BIOSECURE Act. The new draft lays out a 2032 deadline for the separation mandate and adds WuXi Biologics to the list of targets.

Salix adds melody to Xifaxan campaign, running TV spot with 'Scandal' actor Bellamy Young

Salix Pharmaceuticals is stepping up its promotion of Xifaxan in overt hepatic encephalopathy, putting award-winning actor Bellamy Young at the heart of a campaign to raise awareness of the liver disease complication.

AGC Biologics plots roughly 100 layoffs as CDMO industry's post-COVID hangover persists

AGC Biologics, which employs more than 2,500 workers worldwide, has “had to reduce positions at our Seattle and Colorado sites and global functional areas,” a spokesperson confirmed Friday in an emailed statement. The percentage of planned cuts suggests AGC could ultimately lay off around 100 employees.

How Editas 'dragged' Linda Burkly over as CSO after 37 years at Biogen

Linda Burkly, Ph.D., was 37 years into a career at Biogen when Editas CEO Gilmore O’Neill—himself an alum of the neurological disease-focused big biotech—came knocking.

J&J's Megadyne division pulls pediatric electrosurgery pad from market following patient burn recall

The Ethicon branch recalled its Mega Soft and Mega 2000 return electrodes in June 2023 after reports of injuries including third-degree burns.

Bayer’s Midol unveils PeriodTalk campaign to ramp up conversations, education about menstruation

Through the campaign, Midol and Period. plan to open up candid conversations about periods and the menstrual cycle as a whole, while also providing information about the medications and other resources available to help treat period symptoms.

FDA delays decision on Moderna's RSV shot until the end of May

The FDA needs a few more weeks to decide the fate of Moderna's RSV vaccine, the company announced. A decision is now slated for the end of May, as opposed to May 12.
 
Fierce podcasts

Don’t miss an episode

Fulfilling the promise of cell & gene therapies through manufacturing (Part I)

This week’s episode of “The Top Line,” kicks off a series diving into the latest advancements in cell and gene therapy manufacturing. 
 

Resources

Whitepaper

Comprehensive Cell Solutions: Focus on Cellular Therapy Collections

Precision collection of cell therapy source material doesn’t happen by chance. Our new whitepaper illuminates the science and strategies for successful apheresis.
Whitepaper

In Vitro Antibodies – Next-Gen Science Delivers Optimized Candidates

Learn how Specifica’s in vitro antibody discovery platform can deliver better antibodies than traditional immunization approaches.
Whitepaper

Branded Digital Companions in Biopharma

This paper defines “digital companions” in biopharma, explores their value from the patient & company perspectives, & outlines a process for successfully fielding a new digital companion.
Whitepaper

Vaccine Development Challenges in Facing Influenza and COVID-19

Explore the complex considerations of vaccine development for influenza and COVID-19, including the challenges posed by viral evolution and the importance of ongoing research in this paper by vaccine expert, Dr. Lisa Kierstead.
eBook

Designing Patient-Centered Endpoint in Rare Disease Trials

To make every rare disease trial count, we design patient-centric, relevant strategies for sponsors and caregivers to produce impactful results every time.
Whitepaper

Patient Engagement Series

Discover the secrets behind successful patient engagement
Whitepaper

Antibody Profiling: Decoding the Humoral Immune System

Antibody biomarkers are redefining precision medicine, from diagnosing diseases earlier to stratifying patients – download your FREE white paper today!
Whitepaper

Straight to Market in an Autoinjector

The use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors.
 

Industry Events

Drug Development Boot Camp® VIRTUAL | Spring 2024

April ‌10-11, ‌2024

On Helix

Date: ‌4 ‌July ‌2024 ‌- ‌Location: ‌Babraham ‌Research ‌Campus, ‌Cambridge ‌UK

 

Upcoming Fierce Events